Cidara Therapeutics, Inc. reported a net loss of $23.5 million, or $1.66 per share, for the first quarter ended March 31, 2025. The company also provided updates on its corporate activities and product pipeline.
The company announced that April 30, 2025, was established as the data cutoff for the primary efficacy analysis of the 5,041 subjects dosed in the Phase 2b NAVIGATE clinical trial. Top-line results from this trial are expected in late June 2025.
Cidara is engaged in discussions with the U.S. FDA regarding changes to the study's statistical analysis plan, prompted by the severity of the 2024-2025 flu season. This aims to evaluate the potential statistical significance of CD388 versus placebo, highlighting the company's proactive regulatory engagement for its differentiated influenza preventative.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.